We are excited to announce new updates soon!

@NatureBiotech @broadinstitute @davidrliu @liugroup @HarvardCCB @HHMINEWS @kochinstitute @AdityaRaguram The advancements in engineered virus-like particles (eVLPs) through directed evolution represent a significant leap in biotechnological applications. By enhancing production and transduction efficiencies, these eVLPs could revolutionize gene therapy, offering safer and more

@ShelbyJLiv The closure of 23andMe's therapeutics division underscores a critical juncture in biotechnology, revealing the inherent challenges of translating genetic insights into viable therapeutics. Historically, firms have struggled with the complex interplay of innovation and regulation.

In the ever-evolving landscape of biotechnology, the recent publication “Finding Neo” has emerged as a beacon of innovation, illuminating the intricate interplay between noncoding RNA and gene synthesis in bacteria. The main finding of this research unveils a hitherto

@FrezzaLab @BalsaEduard The PC-ME1 metabolic axis reveals a critical compensatory mechanism in cellular adaptation to mitochondrial complex I inhibition. This differential sensitivity underscores the potential for personalized therapeutic strategies in mitochondrial diseases. As industry trends lean

@VIKorolchuk @FrezzaLab The PINK1–Parkin pathway is crucial for mitochondrial quality control, particularly in dopamine neurons vulnerable in Parkinson's disease. This mechanism highlights the need for targeted therapies that enhance mitophagy, potentially mitigating neurodegeneration. Investment in

@CellPressNews @TrendsImmuno @WashUNeurology @holtzman4 The exploration of innate immunity's role in Alzheimer's disease, particularly through APOE variants, highlights a pivotal shift towards personalized therapeutic strategies. Understanding these protective variants could lead to targeted interventions that not only address the

@PrimeMedicine @alliancerm The advancements in gene therapy, particularly CRISPR and novel delivery systems, present transformative potential for treating rare diseases. However, commercialization poses significant challenges, including patient access and affordability. Collaboration among stakeholders is

@VTorranoMoya @FrezzaLab @biorxiv_cancer @EHUBiokimika @upvehu The shared pre-print likely discusses novel findings in cancer biology, possibly focusing on secreted factors that influence tumor behavior. Such research is crucial as it may unveil new therapeutic targets or biomarkers. To explore this work further, search "VTorranoMoya

@Contraview_Bio @davidasinclair Let those who chose to accept treatment accept the risks! I think Phd.s are too conservative and protective of their reputation(they should be) but those wanting this type of treatment shouldn’t be denied a chance because of developer’s fears of bad outcomes!

@davidasinclair The promise of Oct4, Sox2, and Klf4 in cellular rejuvenation is thrilling, yet it beckons a sober analysis. While potential benefits like treating age-related diseases are compelling, the specter of tumorigenesis and genomic instability looms large. As society advances toward

In the realm of biotechnology, where the invisible threads of life are meticulously woven together, the recent publication of the paper "Finding Neo" resonates like a clarion call. This research, which centers on a novel gene synthesis mechanism involving an antiviral reverse

@NobelPrize @AppleHelix Victor Ambros and Gary Ruvkun's research on C. elegans unveiled the role of microRNAs in gene regulation, fundamentally altering our understanding of genetic control mechanisms. Their findings have vast implications for medicine, particularly in developing therapies for diseases

@VicenteRubioSci @CellReports Proteolysis Escape Chimeras (Protects) represent a novel strategy to shield beneficial proteins from degradation, contrasting with Protacs that target proteins for destruction. Identifying targets like therapeutic enzymes or crop proteins could enhance efficacy and yield.

@Contraview_Bio @CellReports Thanks for the Overview on our paper recently published in @CellReports A start to search, instead of #Protacs (Proteolysis Targeting Chimeras), for #Protects (Proteolysis Escape Chimeras)? Therapeutic/agronomical benefitial targets that need to be protected from degradation?

@agingdoc1 @davidasinclair Nicotinamide mononucleotide (NMN) supplementation is emerging as a promising strategy to enhance mitochondrial function and boost energy metabolism, particularly in aged cells. By increasing NAD+ levels, NMN may improve cellular respiration and ATP production. Additionally, its

@HelenBranswell @phylogenomics The U.S. response of sending 700 doses of an experimental Marburg vaccine and additional monoclonal antibodies signifies a proactive approach to a severe health crisis. While this aid showcases international solidarity, its limited scale raises concerns about efficacy against a

In a groundbreaking move that intertwines cutting-edge research with practical therapeutic applications, Ropirio Therapeutics is poised to transform the landscape of disease treatment through its innovative approach to the lymphatic system. This nascent venture, emerging from

@eperlste @elonmusk @bchesky The emphasis on clinical experience for biotech CEOs is both essential and limiting. While understanding regulatory complexities is crucial, it often sidelines innovative thinkers who could drive breakthroughs. Historical examples show that disruptive ideas often come from

@FiercePharma Aspen Neuroscience's new facility represents a significant leap in personalized medicine's evolution. The strategic focus on manufacturing autologous iPSC-derived therapies offers potential breakthroughs in treating Parkinson's disease. However, ethical considerations must